NEW YORK, July 20, 2015 /PRNewswire/ --
ACI Association has initiated research coverage on Ohr Pharmaceutical, Inc. (NASDAQ: OHRP). Select highlights from the internally released reports are being made available to the general public (included below), with access to the entirety of the research available to new members.
Today, membership is open to readers on a complementary basis at the following URL: http://www.aciassociation.com/?c=OHRP
Highlights from our OHRP Report include:
- Final Result of Phase II Clinical Study - On July 13, 2015, the ophthalmology research and development company Ohr Pharmaceutical, Inc. announced the outcome of Phase II investigator sponsored clinical trial of OHR-102 (0.2% Squalamine lactate ophthalmic solution). The Company informed that the final result of the trial, which was conducted in patients with macular edema secondary to branch (BRVO) and central retinal vein occlusion (CRVO), was positive. The study demonstrated that OHR-102 combination therapy enhances visual recovery in macular edema secondary to retinal vein occlusion.
- Data Presentation - The data was presented by a retina specialist John Wroblewski at retina specialist on July 11 at the 2015 Annual Meeting of the American Society of Retina Specialists (ASRS) in Vienna, Austria. This data included the final analysis of patients that, following a 10 week initial combination treatment period, were randomized to receive either continued OHR-102 + Lucentis PRN therapy or only Lucentis monotherapy PRN through week 38.
- Study Design - The Company stated that for the 38 week, investigator sponsored, Phase II clinical trial, 20 treatment naïve patients were enrolled with macular edema due to retinal vein occlusion. While all the patients received OHR-102 topically for the first 10 weeks of treatment, two injections of Lucentis were injected to them at week 2 and week 6. In the later stage of the study, patients were randomized 1:1 at week 10 to either continue administering OHR-102 eye drops or discontinue drops for the remainder of the study. Retreatment with Lucentis injections were administered monthly as needed (PRN) through week 38 based on OCT criteria.
- Combination Therapy versus only Lucentis - The data demonstrated that the patients who continued to receive a combination of topical OHR-102 BID plus Lucentis®, following an initial 10 week combination therapy treatment period, achieved greater visual acuity gains than the control group who received Lucentis alone. After the initial combination therapy phase, the mean gain in visual acuity from week 10 to week 38 was +7.4 letters for patients who continued treatment with OHR-102 + Lucentis PRN compared with +3.1 letters in those receiving Lucentis PRN alone. At week 38, 80% of patients in the OHR-102 + Lucentis treated group had a gain in visual acuity, compared with 50% of patients treated with Lucentis alone. Additionally, at week 38, none of the patients in the OHR-102 + Lucentis treated group lost any vision.
To find out how this influences our rating on Ohr Pharmaceutical, Inc., read the full report in its entirety here: http://www.aciassociation.com/?c=OHRP
About ACI Association:
Active Charter Investors Association ("ACI Association") produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. ACI Association has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
ACI Association has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the "CFA®"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer and the CFA® have not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author, the Reviewer, or the CFA® (collectively referred to as the "Production Team") in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein.
ACI Association, the Author, the Reviewer and the CFA® (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither ACI Association nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.aciassociation.com/.
ACI Association is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia. Do not send email to robottrap (at) aciassociation.com.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.